eMedicine Specialties > Dermatology > Diseases of the Vessels

Klippel-Trenaunay-Weber Syndrome

Author: Camila K Janniger, MD, Clinical Professor of Dermatology, Clinical Associate Professor of Pediatrics, Chief of Pediatric Dermatology, New Jersey Medical School
Contributor Information and Disclosures

Updated: Jun 2, 2009

Introduction

Background

Klippel-Trenaunay syndrome is characterized by a triad of port-wine stain, varicose veins, and bony and soft tissue hypertrophy involving an extremity.

In 1900, noted French physicians Klippel and Trenaunay first described a syndrome in 2 patients presenting with a port-wine stain and varicosities of an extremity associated with hypertrophy of the affected limb's bony and soft tissue. They termed the syndrome "naevus vasculosus osteohypertrophicus." In 1907, Parkes Weber, unaware of Klippel and Trenaunay's report, described a patient with the 3 aforementioned symptoms as well as an arteriovenous malformation of the affected extremity. He termed the process hemangiectatic hypertrophy.

Today, conflicting opinion exists in the literature as whether to separately designate the original triad as Klippel-Trenaunay syndrome and the triad with the addition of arteriovenous malformation as Parkes Weber syndrome. Making the distinction is probably wise given the increased morbidity associated with arteriovenous malformations. For this discussion, the 2 types are considered together.

Pathophysiology

The exact cause of Klippel-Trenaunay-Weber syndrome (KTWS) remains to be elucidated, although several theories exist. Bliznak and Staple suggested intrauterine damage to the sympathetic ganglia or intermediolateral tract leading to dilated microscopic arteriovenous anastomoses as the cause.1 Servelle believes that deep vein abnormalities, with resultant obstruction of venous flow, lead to venous hypertension, the development of varices, and limb hypertrophy.2 Baskerville et al contend that a mesodermal defect during fetal development causes maintenance of microscopic arteriovenous communications.3 Finally, McGrory and Amadio believe that an underlying mixed mesodermal and ectodermal dysplasia is likely responsible for the development of KTWS.4

Most cases are sporadic, although a few cases in the literature report an autosomal dominant pattern of inheritance.5 A case report of KTWS in a monozygotic twin with an unaffected twin advances the theory of a paradominant inheritance pattern.6 This theory suggests that KTWS is produced by a single gene defect lethal in individuals who are homozygous for this gene. Heterozygotes carry the gene but are unaffected. The disease manifests in individuals who demonstrate loss of heterozygosity from a somatic mutation during embryogenesis. In these individuals, only the skin region harboring this cell population demonstrates the KTWS mutation.

The association between the angiogenic factor gene AGGF1 and KTS appears to be significant.7 Common AGGF1 variants may confer risk of KTWS.

Kihiczak et al report that KTWS may result from a pathogenic gene for vascular and tissue overgrowth.8

Race

No racial predilection is documented.

Sex

KTWS affects females and males equally.

Age

KTWS presents at birth or during early infancy or childhood.

Clinical

History

  • Klippel-Trenaunay-Weber syndrome (KTWS) generally affects a single extremity, although cases of multiple affected limbs have been reported. The leg is the most common site followed by the arms, the trunk, and rarely the head and the neck. One report describes only upper limb involvement.9
  • Most patients demonstrate all 3 signs of the clinical syndrome: port-wine stain, varicose veins, and bony and soft tissue hypertrophies.
  • In a series of 252 patients at the Mayo Clinic, 63% of patients had all 3 features and 37% had 2 of the 3 features. Port-wine stain was seen in 98% of patients, varicosities or venous malformations in 72%, and limb hypertrophy in 67%. Atypical veins, including lateral veins and persistent sciatic vein, were present in 72% of patients. Finally, deep venous abnormalities included aneurysmal dilation, hypoplasia, aplasia, and absent or incompetent valves.

Physical

  • The capillary hemangioma or port-wine stain usually presents first.
    • This hemangioma has a distinct, linear border that respects the midline. Hemangioma is often noted on the lateral aspect of the limb.
    • It is typically of the nevus flammeus type, but cavernous hemangiomas or lymphangiomas may also occur. Nevus flammeus is a salmon pink patch, sometimes with a verrucous quality, which evolves to a deep purple color with time. Unlike strawberry hemangiomas, the port-wine stain hemangioma possesses neither a proliferative nor a regressing phase.
    • Hemangioma depth is variable. It may be limited to the skin or extend deeper to subcutaneous tissue, including muscle and bone. Visceral organs, such as the pleura, the spleen, the liver, the bladder, and the colon may also be affected. Visceral organ involvement portends greater morbidity secondary to internal hemorrhage that may manifest as hematuria or hematochezia.
    • If large enough, cutaneous hemangiomas may sequester platelets, leading to possible Kasabach-Merritt syndrome, a type of consumptive coagulopathy. The hemangioma often overlies the vascular malformation.
  • Varicose veins in KTWS are congenital.
    • The Klippel-Trenaunay vein is a large, lateral, superficial vein sometimes seen at birth. This vein begins in the foot or the lower leg and travels proximally until it enters the thigh or the gluteal area. Otherwise, varicosities may not be clinically evident until the child begins to ambulate.
    • Varicosities may be extensive, though they often spare the saphenous distribution. They are seen below the knee, laterally above the knee, and occasionally in the pelvic region. Varicosities may affect the superficial, deep, and perforating venous systems.
    • Surgical exploration has demonstrated atresia and agenesis of deep veins, compression due to fibrous bands, aberrant arteries, abnormal muscles, or venous sheaths.
    • Rarely, varicosities have been found in the bladder, the colon, and the pulmonary vessels.
    • Varicosities may remain stable in size or gradually expand. Pain and lymphedema are commonly reported. These symptoms may worsen during pregnancy.
  • Arteriovenous fistulas, the feature that distinguishes Klippel-Trenaunay syndrome from Parkes-Weber syndrome, are rarely found in the affected extremity.
    • If present, they can occasionally be palpated as a pulsatile mass, thrill, or bruit on physical examination.
    • Hyperthermia and a positive Branham sign (bradycardia with the application of compression on an artery proximal to the malformation) are also indicators of an arteriovenous malformation.
  • Bony and soft tissue hypertrophies are the third sign of KTWS.
    • Limb hypertrophy can be secondary to increased length (bony involvement) and/or increased girth (soft tissue involvement). Hypertrophy may be appreciated at birth. It usually progresses during the first years of life. A greater degree of hypertrophy may be seen in patients with coexisting arteriovenous malformation. Although lymphedema is also seen in patients, true hypertrophy of the affected soft tissues is present.
    • Limb discrepancies of as much as 12 cm have been reported.
    • Occasionally, the involved limb may be atrophied rather than hypertrophied.
  • Other features include lymphatic obstruction, spina bifida, hypospadias, polydactyly, syndactyly, oligodactyly, hyperhidrosis, hypertrichosis, paresthesia, decalcification of involved bones, chronic venous insufficiency, stasis dermatitis, poor wound healing, ulceration, thrombosis, angiosarcoma, and emboli.10,11

Causes

See Pathophysiology.

More on Klippel-Trenaunay-Weber Syndrome

Overview: Klippel-Trenaunay-Weber Syndrome
Differential Diagnoses & Workup: Klippel-Trenaunay-Weber Syndrome
Treatment & Medication: Klippel-Trenaunay-Weber Syndrome
Follow-up: Klippel-Trenaunay-Weber Syndrome
References

References

  1. Bliznak J, Staple TW. Radiology of angiodysplasias of the limb. Radiology. Jan 1974;110(1):35-44. [Medline].

  2. Servelle M. Klippel and Trenaunay's syndrome. 768 operated cases. Ann Surg. Mar 1985;201(3):365-73. [Medline].

  3. Baskerville PA, Ackroyd JS, Browse NL. The etiology of the Klippel-Trenaunay syndrome. Ann Surg. Nov 1985;202(5):624-7. [Medline].

  4. McGrory BJ, Amadio PC. Klippel-Trenaunay syndrome: orthopaedic considerations. Orthop Rev. Jan 1993;22(1):41-50. [Medline].

  5. Ceballos-Quintal JM, Pinto-Escalante D, Castillo-Zapata I. A new case of Klippel-Trenaunay-Weber (KTW) syndrome: evidence of autosomal dominant inheritance. Am J Med Genet. Jun 14 1996;63(3):426-7. [Medline].

  6. Hofer T, Frank J, Itin PH. Klippel-Trenaunay syndrome in a monozygotic male twin: supportive evidence for the concept of paradominant inheritance. Eur J Dermatol. Sep-Oct 2005;15(5):341-3. [Medline].

  7. Hu Y, Li L, Seidelmann SB, et al. Identification of association of common AGGF1 variants with susceptibility for Klippel-Trenaunay syndrome using the structure association program. Ann Hum Genet. Sep 2008;72:636-43. [Medline].

  8. Kihiczak GG, Meine JG, Schwartz RA, Janniger CK. Klippel-Trenaunay syndrome: a multisystem disorder possibly resulting from a pathogenic gene for vascular and tissue overgrowth. Int J Dermatol. Aug 2006;45(8):883-90. [Medline].

  9. Akcali C, Inaloz S, Kirtak N, Ozkur A, Inaloz S. A case of Klippel-Trenaunay syndrome involving only upper limbs. G Ital Dermatol Venereol. Aug 2008;143(4):267-9. [Medline].

  10. Furness PD 3rd, Barqawi AZ, Bisignani G, Decter RM. Klippel-Trenaunay syndrome: 2 case reports and a review of genitourinary manifestations. J Urol. Oct 2001;166(4):1418-20. [Medline].

  11. Ploegmakers MJ, Pruszczynski M, De Rooy J, Kusters B, Veth RP. Angiosarcoma with malignant peripheral nerve sheath tumour developing in a patient with klippel-trénaunay-weber syndrome. Sarcoma. 2005;9(3-4):137-40. [Medline].

  12. Li X, Tian J. Multidetector row computed tomography arteriography in the preoperative assessment of patients with Klippel-Trénaunay syndrome. J Am Acad Dermatol. Feb 2009;60(2):345-6; author reply 346. [Medline].

  13. Lee A, Driscoll D, Gloviczki P, Clay R, Shaughnessy W, Stans A. Evaluation and management of pain in patients with Klippel-Trenaunay syndrome: a review. Pediatrics. Mar 2005;115(3):744-9. [Medline].

  14. Andreasen KR, Tabor A, Weber T. Klippel-Trenaunay-Weber syndrome in pregnancy and at delivery. J Obstet Gynaecol. Jan 1999;19(1):78-9. [Medline].

  15. Hergesell K, Kroger K, Petruschkat S, Santosa F, Herborn C, Rudofsky G. Klippel-Trenaunay syndrome and pregnancy. Int Angiol. Jun 2003;22(2):194-8. [Medline].

  16. Spicer MS, Goldberg DJ, Janniger CK. Lasers in pediatric dermatology. Cutis. May 1995;55(5):270-2, 278-80. [Medline].

  17. Yildiz F, Yilmaz M, Cengiz M, et al. Radiotherapy in the management of Klippel-Trénaunay-Weber syndrome: report of two cases. Ann Vasc Surg. Jul 2005;19(4):566-71. [Medline].

  18. Huang Y, Jiang M, Li W, Lu X, Huang X, Lu M. Endovenous laser treatment combined with a surgical strategy for treatment of venous insufficiency in lower extremity: a report of 208 cases. J Vasc Surg. Sep 2005;42(3):494-501; discussion 501. [Medline].

  19. Willis-Owen CA, Cobb JP. Total hip arthroplasty in Klippel-Trenaunay syndrome. Ann R Coll Surg Engl. Nov 2008;90(8):W6-8. [Medline].

  20. Aelvoet GE, Jorens PG, Roelen LM. Genetic aspects of the Klippel-Trenaunay syndrome. Br J Dermatol. Jun 1992;126(6):603-7. [Medline].

  21. Atherton DJ. Naevi and other developmental defects. In: Rook, Wilkinson, Ebling, eds. Textbook of Dermatology. London: Blackwell Science; 1998:585-588.

  22. Fishman SJ, Mulliken JB. Hemangiomas and vascular malformations of infancy and childhood. Pediatr Clin North Am. Dec 1993;40(6):1177-200. [Medline].

  23. Gloviczki P, Stanson AW, Stickler GB, et al. Klippel-Trenaunay syndrome: the risks and benefits of vascular interventions. Surgery. Sep 1991;110(3):469-79. [Medline].

  24. Jacob AG, Driscoll DJ, Shaughnessy WJ, Stanson AW, Clay RP, Gloviczki P. Klippel-Trénaunay syndrome: spectrum and management. Mayo Clin Proc. Jan 1998;73(1):28-36. [Medline].

  25. Meine JG, Schwartz RA, Janniger CK. Klippel-Trenaunay-Weber syndrome. Cutis. Sep 1997;60(3):127-32. [Medline].

  26. Ring DS, Mallory SB. What syndrome is this? Klippel-Trenaunay syndrome. Pediatr Dermatol. Mar 1992;9(1):80-2. [Medline].

  27. Samuel M, Spitz L. Klippel-Trenaunay syndrome: clinical features, complications and management in children. Br J Surg. Jun 1995;82(6):757-61. [Medline].

  28. Spicer MS, Schwartz RA, Janniger CK. Nevus flammeus. Cutis. Nov 1994;54(5):315-20. [Medline].

  29. Spitz J. Genodermatoses: A Full Color Clinical Guide to Genetic Skin Disorders. Baltimore: Williams & Wilkins; 1996.

  30. Wilson CL, Song LM, Chua H, et al. Bleeding from cavernous angiomatosis of the rectum in Klippel-Trenaunay syndrome: report of three cases and literature review. Am J Gastroenterol. Sep 2001;96(9):2783-8. [Medline].

Further Reading

Keywords

Klippel-Trenaunay-Weber syndrome, KTWS, Parkes Weber syndrome, Klippel-Trenaunay syndrome, KTS, port-wine stain, varicose veins, bony and soft tissue hypertrophy, arteriovenous malformation

Contributor Information and Disclosures

Author

Camila K Janniger, MD, Clinical Professor of Dermatology, Clinical Associate Professor of Pediatrics, Chief of Pediatric Dermatology, New Jersey Medical School
Camila K Janniger, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

Medical Editor

Jean Paul Ortonne, MD, Chair, Department of Dermatology, Professor, Hospital L'Archet, Nice University, France
Jean Paul Ortonne, MD is a member of the following medical societies: American Academy of Dermatology and American Dermatological Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center
Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Lester F Libow, MD, Dermatopathologist, South Texas Dermatopathology Laboratory
Lester F Libow, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, and Texas Medical Association
Disclosure: Nothing to disclose.

CME Editor

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology
Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds None; Genentech Consulting fee Consulting; Centocor Consulting fee Consulting; Centocor Grant/research funds None; Covance Consulting fee Consulting; Shire  Consulting

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.